Reviewing Lite Strategy (LITS) & Its Competitors

Lite Strategy (NASDAQ:LITS) is one of 451 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it compare to its peers? We will compare Lite Strategy to related businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Lite Strategy and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lite Strategy	1	0	0	0	1.00
Lite Strategy Competitors	4783	9955	15976	368	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 88.89%. Given Lite Strategy’s peers stronger consensus rating and higher probable upside, analysts plainly believe Lite Strategy has less favorable growth aspects than its peers.

Profitability

This table compares Lite Strategy and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lite Strategy	N/A	-69.70%	-60.80%
Lite Strategy Competitors	-2,625.49%	-359.63%	-43.39%

Institutional & Insider Ownership

52.4% of Lite Strategy shares are held by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 3.1% of Lite Strategy shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Lite Strategy and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lite Strategy	$65.30 million	-$15.94 million	-0.39
Lite Strategy Competitors	$439.20 million	-$68.89 million	-8.97

Lite Strategy’s peers have higher revenue, but lower earnings than Lite Strategy. Lite Strategy is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Lite Strategy has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Lite Strategy’s peers have a beta of 10.31, meaning that their average stock price is 931% more volatile than the S&P 500.

Summary

Lite Strategy peers beat Lite Strategy on 8 of the 13 factors compared.

About Lite Strategy

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.